The Clivia series Diagnostic Ultrasound System is applicable for adults, pediatric patients and neonates. It intended for use in Fetal/Obstetrics, Abdominal/GYN, Pediatrics, Small Organ(breast, thyroid, testes), Neonatal Cephalic, Adult Cephalic, Trans-rectal, Musculoskeletal (Conventional), Musculoskeletal (Superticial), Thoracic/Pleural, Cardiac Adult, Cardiac Pediatric), peripheral vessel and Urology exams.

The operator for Clivia series Diagnostic Ultrasound System is intended for professional clinical staff or the qualified and trained personnel with experience in the use of ultrasound diagnostic equipment. The device is intended to be used in hospital or clinics.

Modes of operation include: B-Mode, Color Mode, Power (Dirpower)-Mode, PW Doppler Mode, CW Doppler Mode, 3D/4D, Holo PW, Tissue Harmonic Imaging, Tissue Doppler Imaging(TDI), Anatomic M(AMM) and combined mode.

Device Description

The proposed Clivia series Diagnostic Ultrasound System is a general-purpose, Track 3, diagnostic ultrasound device, intended for ultrasound imaging, measurement and analysis of the human body and fluid that provides digital acquisition, processing and display capabilities.

The Clivia series Diagnostic Ultrasound System can be controlled both by touch screen or the control panel. Its basic function is to acquire and display ultrasound data in B-Mode, M-Mode, Color-Mode, Power(Dirpower)-Mode, PW-Mode, 3D/4D, Holo PW, Anatomic M(AMM), Tissue Doppler Imaging(TDI) and the combined modes. The system can also measure anatomical structures and offer software analysis packages performance to provide information based on which the competent health care professionals can make the diagnosis.

Ten different models of probes are available for the Clivia series, that is C6-1B-H, C6-2-H, C9-3-H, L15-4NB-H, L22-10-H, LH15-6-H, SP5-1-H, P8-3-H, EV11-3-H, D7-2-H.

The Clivia series Diagnostic Ultrasound System has the capability for displaying the patient's ECG and trace synchronized to the scanned image. This allows the user to view an image from a specific time of the ECG signal. ECG is not intended for monitoring or diagnosis.

The Clivia series Diagnostic Ultrasound System has four batteries in total that allows for scanning or other operation without the need to plug in to an electrical outlet. The system is capable of wireless communication and a barcode reader is available to be used as an input device. System meets DICOM requirements to support users image storage and archiving needs and allows for output to printing devices.

AI/ML Overview

The provided text describes the Clivia series Diagnostic Ultrasound System. However, it does not include details about acceptance criteria for performance metrics (such as sensitivity, specificity, accuracy, etc.) or a study that proves the device meets such criteria in terms of diagnostic performance.

The document primarily focuses on demonstrating substantial equivalence to a predicate device (GE Venue K180599) and adherence to general safety and regulatory standards.

Here's a breakdown of the specific information requested, based on the provided text:

A table of acceptance criteria and the reported device performance:
The document does not provide a table of acceptance criteria related to diagnostic performance (e.g., sensitivity, specificity, or image quality metrics) or reported device performance against such criteria. It states that "The non-clinical data support the safety of the device and the performance testing report demonstrate that the Clivia series Diagnostic Ultrasound System should perform as intended in the specified use conditions." but does not elaborate on specific performance metrics.
Sample size used for the test set and the data provenance:
The document explicitly states: "The subject of this premarket submission, Clivia series Diagnostic Ultrasound System, did not require clinical studies to support substantial equivalence." Therefore, there is no test set sample size or data provenance related to diagnostic performance presented.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
As no clinical studies were performed for diagnostic performance, there were no experts mentioned for establishing ground truth for a test set.
Adjudication method (e.g., 2+1, 3+1, none) for the test set:
As no clinical studies were performed for diagnostic performance, there is no mention of an adjudication method.
If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
No MRMC study was done, and the device is a diagnostic ultrasound system, not an AI-assisted device for improving human reader performance.
If a standalone (i.e. algorithm only without human-in-the loop performance) was done:
No standalone performance study for an algorithm was done, as this is a diagnostic ultrasound system, not an AI-driven image analysis algorithm.
The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
No ground truth was established for diagnostic performance as no clinical studies are mentioned.
The sample size for the training set:
Not applicable, as this document does not describe the development or testing of a machine learning algorithm that would require a training set.
How the ground truth for the training set was established:
Not applicable, as this document does not describe the development or testing of a machine learning algorithm that would require a training set.

Summary of available performance data from the text:

The "Performance Data" section (Section 6) of the document details non-clinical performance data provided in support of substantial equivalence. These include:

Biocompatibility testing: Conducted using ISO-10993 standards and included cytotoxicity, sensitization, and irritation tests.
Electrical safety and electromagnetic compatibility (EMC) testing: Complies with IEC 60601-1, IEC 60601-2-37 for safety, and IEC 60601-1-2 for EMC.
Software Verification and Validation Testing: Conducted in accordance with FDA guidance for "Moderate" level of concern software.
Acoustic testing: Conducted in accordance with NEMA UD 2-2004 (R2009) acoustic output measurement standard, ensuring acoustic power levels are below FDA limits.

The document concludes that "The differences between the Clivia series Diagnostic Ultrasound System and its predicate device do not raise different questions of safety and effectiveness. The non-clinical data support the safety of the device and the performance testing report demonstrate that the Clivia series Diagnostic Ultrasound System should perform as intended in the specified use conditions."

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

Shenzhen Wisonic Medical Technology Co., Ltd. % Jiang Xiaosan Management Representative 1st, 2nd, 5th & 6th Floor, NO.6 Building, Pingshan Technology Park, Taoyuan Street, Nanshan District Shenzhen, Guangdong 518055 CHINA

December 2, 2021

Re: K211886

Trade/Device Name: Clivia series Diagnostic Ultrasound System Regulation Number: 21 CFR 892.1550 Regulation Name: Ultrasonic pulsed doppler imaging system Regulatory Class: Class II Product Code: IYN, IYO, ITX Dated: October 25, 2021 Received: November 1, 2021

Dear Jiang Xiaosan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

{1}------------------------------------------------

801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

For

Thalia T. Mills, Ph.D. Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K211886

Device Name Clivia series Diagnostic Ultrasound System

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

K211886

510(k) Summary

1. Submitter

Manufacturer:	Shenzhen Wisonic Medical Technology Co., Ltd.
Address:	1st, 2nd, 5th & 6th Floor, NO.6 Building, Pingshan Technology Park,Taoyuan Street, Nanshan District, Shenzhen. Guangdong, 518055, P.R.CHINA
Contact person:	Name:	Jiang Xiaosan
	Phone:	+86-755-86007788
	Fax:	+86-755-86007799
Date prepared:	June 08, 2021
2. Device
Name of Device:	Clivia series Diagnostic Ultrasound System
Models:	Clivia 90Elite, Clivia 90Exp, Clivia 90Nova, Clivia 90, Clivia 90T,Clivia 90Pro, Clivia 90Plus, Clivia 90Go
Common/Usual Name:	Diagnostic Ultrasound System
Regulatory Class	II
Product Code:	IYN, IYO, ITX

3. Device Description

Ten different models of probes are available for the Clivia series, that is C6-1B-H, C6-2-H, C9-3-H, L15-4NB-H, L22-10-H, LH15-6-H, SP5-1-H, P8-3-H, EV11-3-H, D7-2-H.

{4}------------------------------------------------

1. Indications for Use
  The Clivia series Diagnostic Ultrasound System is applicable for adults, pregnant women, pediatric patients and neonates. It intended for use in Fetal/Obstetrics, Abdominal/GYN, Pediatrics, Small Organ(breast, thyroid, testes), Neonatal Cephalic, Adult Cephalic, Trans-rectal, Trans-vaginal, Musculoskeletal (Conventional), Musculoskeletal (Superficial), Thoracic/Pleural, Cardiac Adult, Cardiac Pediatric), peripheral vessel and Urology exams.

PredicateDevice	Manufacturer	Device Name	510(k) Number
Predicatedevice	GEMedical SystemsUltrasound and Primary CareDiagnostics, LLC	Venue	K180599
Referencedevice	ShenzhenMindrayBio-medical Electronics Co.,LTD.	DC-80/DC-80PRO/DC-80EXP/DC-80S/DC-85 DiagnosticUltrasound System	K173471
Referencedevice	Shenzhen Wisonic MedicalTechnology Co., Ltd.	Navi e/Navi s/Navi X DiagnosticUltrasound System	K180461

Comparison of Technological Characteristics between Proposed Subject Device and Predicate Device

Clivia series Diagnostic Ultrasound System is substantially equivalent to the predicate devices with regards to intended use, imaging capabilities, technological characteristics and safety and effectiveness:

The Proposed device and predicate device Venue (K180599) have similar intended use, the intend ● use of the Proposed device are covered in the intended use of the predicate device.
The proposed device has similar operation modes to the predicate device Venue (K180599), except for Holo PW. The Holo PW has been cleared in reference device (K180461);
The proposed device has the same function with the predicate device Venue (K180599), except for wiGuide. For wiGuide, it has identical operating principals and specifications as the NGS function of the reference device (K180461), the difference between wiGuide and NGS is only the name.

{5}------------------------------------------------

wisonic

The proposed device has similar ports to the predicate device Venue (K180599)
The proposed device has similar peripheral devices to the predicate device Venue (K180599), except for Magnetized Cup and Foot switch. For Magnetized Cup, it has been cleared in reference device (K180461). For Foot switch, it can be considered same as reference device (K173471).
The acoustic power levels of the proposed device are below the limits of FDA, which is the same as the predicate device (K180599).
The system is manufactured with materials which have been evaluated and found to be safe for the intended use of the device.
The proposed device and predicate device Venue (K180599) have been designed in compliance with approved electrical and physical safety standards.

The difference in technological characteristics do not raise different questions of safety and effectiveness as compared to the predicate device.

6. Performance Data

The following performance data were provided in support of the substantial equivalence determination.

6.1 Biocompatibility testing

The biocompatibility evaluation for the Clivia series Diagnostic Ultrasound System was conducted in accordance with the FDA Blue Book Memorandum #G95-1 "Use of International Standard ISO-10993, 'Biological Evaluation of Medical Devices Part 1: Evaluation and Testing,' and International Standard ISO 10993-1 "Biological Evaluation of Medical Devices - Part 1: Evaluation and Testing Within a Risk Management Process," as recognized by FDA. The battery of testing included the following tests:

Cytotoxicity
Sensitization
Irritation

6.2 Electrical safety and electromagnetic compatibility (EMC)

Electrical safety and EMC testing were conducted on the Clivia series Diagnostic Ultrasound System. The system complies with the IEC 60601-1 and IEC 60601-2-37 standards for safety and the IEC 60601-1-2 standard for EMC.

6.3 Software Verification and Validation Testing

Software verification and validation testing were conducted and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices". The software for this device was considered as a "Moderate" level of concern.

{6}------------------------------------------------

wisonic

Acoustic testing is conducted on the Clivia series Diagnostic Ultrasound System in accordance with the NEMA UD 2-2004 (R2009), acoustic output measurement standard for diagnostic ultrasound equipment revision 3.

6.5 Clinical study

The subject of this premarket submission, Clivia series Diagnostic Ultrasound System, did not require clinical studies to support substantial equivalence.

7. Conclusion

The differences between the Clivia series Diagnostic Ultrasound System and its predicate device do not raise different questions of safety and effectiveness. The non-clinical data support the safety of the device and the performance testing report demonstrate that the Clivia series Diagnostic Ultrasound System should perform as intended in the specified use conditions.

From the results of performance data described, Wisonic concludes that the Clivia series Diagnostic Ultrasound System is substantially equivalent to the predicate device in terms of safety and effectiveness.

Regulation Number and Section

§ 892.1550 Ultrasonic pulsed doppler imaging system.

(a)
Identification. An ultrasonic pulsed doppler imaging system is a device that combines the features of continuous wave doppler-effect technology with pulsed-echo effect technology and is intended to determine stationary body tissue characteristics, such as depth or location of tissue interfaces or dynamic tissue characteristics such as velocity of blood or tissue motion. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.